Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dextran-docosahexaenoic acid-cabazitaxel
- Development stage
- Preclinical
- Lead developer
- Shandong University
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Dextran-docosahexaenoic acid-cabazitaxel (dextran-DHA-CTX) is an experimental dual drug conjugate developed to enhance the therapeutic profile of cabazitaxel, a second-generation taxane used for metastatic castration-resistant prostate cancer. The conjugate is synthesized by covalently linking docosahexaenoic acid (DHA), an omega-3 fatty acid, to cabazitaxel and subsequently attaching this complex to a bifunctionalized dextran polymer backbone. This design aims to improve the water solubility of cabazitaxel and facilitate tumor-selective accumulation through the enhanced permeability and retention (EPR) effect. Preclinical evaluations in xenografted nude mice bearing PC-3 and DU145 prostate cancer cells demonstrated that while the conjugate improves solubility and antitumor activity compared to free cabazitaxel, it is less potent than its gamma-linolenic acid (GLA) counterpart, dextran-GLA-CTX. The research was conducted by investigators at Shandong University in collaboration with Santolecan Pharmaceuticals.
- Other names
- dextran-DHA-cabazitaxelDHA-CTX-dextran conjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on dextran-docosahexaenoic acid-cabazitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dextran-docosahexaenoic acid-cabazitaxel.